ESMO Guidance for Reporting Oncology real-World evidence (GROW)

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329

Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Elm, E. V., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · BMJ · doi:10.1136/bmj.39335.541782.ad · Cited by 10,766

The Reporting of Studies Conducted Using Observational Routinely-Collected Health Data (RECORD) statement.

Benchimol, E. I., Smeeth, L., Guttmann, A., Harron, K., Moher, D., Petersen, I., Sørensen, H. T., von Elm, E., Langan, S. M., & RECORD Working Committee (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001885 · Cited by 5,749

To Explain or to Predict?

Galit Shmueli, A. (2010) · Statistical Science · doi:10.1214/10-sts330 · Cited by 3,392

Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1.

Hernán, M. A., & Robins, J. M. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kwv254 · Cited by 3,115

Statistics versus machine learning

Bzdok, D., Altman, N., & Krzywinski, M. (2018) · Nature Methods · doi:10.1038/nmeth.4642 · Cited by 1,508

Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials

Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445

Checklist for Artificial Intelligence in Medical Imaging (CLAIM): a guide for authors and reviewers

Mongan, J., Moy, L., & Kahn, C. E. (2020) · Radiology: Artificial Intelligence · doi:10.1148/ryai.2020200029 · Cited by 1,443

REporting recommendations for tumour MARKer prognostic studies (REMARK).

for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics, McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602678 · Cited by 1,394

Identifying the PECO: A framework for formulating good questions to explore the association of environmental and other exposures with health outcomes

Morgan, R. L., Whaley, P., Thayer, K. A., & Schünemann, H. J. (2018) · Environment International · doi:10.1016/j.envint.2018.07.015 · Cited by 1,282

BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update

Reig, M., Sanduzzi‐Zamparelli, M., Forner, A., Rimola, J., Ferrer, J., Burrel, M., García‐Criado, Á., Díaz, A., Llarch, N., Iserte, G., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.10.020 · Cited by 253

A guide to artificial intelligence for cancer researchers

Pérez-López, R., Laleh, N. G., Mahmood, F., & Kather, J. N. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00694-7 · Cited by 227

Advances in molecular pathology and therapy of non-small cell lung cancer

Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197

Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions

Lotter, W., Hassett, M. J., Schultz, N., Kehl, K. L., Van Allen, E. M., & Cerami, E. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1199 · Cited by 196

Privacy-preserving large language models for structured medical information retrieval

Wiest, I. C., Ferber, D., Zhu, J., van Treeck, M., Meyer, S. K., Juglan, R., Carrero, Z. I., Paech, D., Kleesiek, J., Ebert, M., et al. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01233-2 · Cited by 184

Large language model use in clinical oncology

Carl, N., Schramm, F., Haggenmüller, S., Kather, J. N., Hetz, M. J., Wies, C., Michel, M. S., Wessels, F., & Brinker, T. J. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00733-4 · Cited by 85

Artificial intelligence in liver cancer — new tools for research and patient management

Caldéraro, J., Žigutytė, L., Truhn, D., Jaffe, A., & Kather, J. N. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00919-y · Cited by 73

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

Westphalen, C. B., Martins-Branco, D. A., Beal, J. R., Cardone, C., Coleman, N., Schram, A. M., Halabi, S., Michiels, S., Yap, C., André, F., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.07.730 · Cited by 74

Progress and challenges of artificial intelligence in lung cancer clinical translation

Zhu, E., Muneer, A., Zhang, J., Yang, X., Li, X., Zhou, C., Heymach, J. V., Wu, J., & Le, X. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00986-7 · Cited by 59

Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study

Provenzano, L., Dieci, M. V., Curigliano, G., Giuliano, M., Botticelli, A., Lambertini, M., Rizzo, G., Pedersini, R., Sirico, M., Verde, N. M. L., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.03.023 · Cited by 48

Generating and using real-world data: A worthwhile uphill battle

Verkerk, K., & Voest, E. E. (2024) · Cell · doi:10.1016/j.cell.2024.02.012 · Cited by 41

Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Alaklabi, S., Roy, A. M., Zagami, P., Chakraborty, A., Held, N. M., Elijah, J., George, A. M., Attwood, K. M., Shaikh, S. S., Chaudhary, L. N., et al. (2024) · JCO Oncology Practice · doi:10.1200/op.24.00242 · Cited by 33

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry

Cortellini, A., Brunetti, L., Fazio, G. R. D., Garbo, E., Pinato, D. J., Naidoo, J., Katz, A., Loza, M., Neal, J. W., Genova, C., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010674 · Cited by 33

From Text to Tables: A Local Privacy Preserving Large Language Model for Structured Information Retrieval from Medical DocumentsPreprint

Wiest, I. C., Ferber, D., Zhu, J., van Treeck, M., Meyer, S. K., Juglan, R., Carrero, Z. I., Paech, D., Kleesiek, J., Ebert, M. P., et al. (2023) · medRxiv · doi:10.1101/2023.12.07.23299648 · Cited by 28

Predicting resistance to chemotherapy using chromosomal instability signatures

Thompson, J. S., Madrid, L., Hernando, B., Sauer, C. M., Vias, M., Escobar-Rey, M., Leung, W., Garcia-Lopez, D., Huckstep, J., Sekowska, M., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02233-y · Cited by 29

Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs

Dong, S., Li, X., Huang, Q., Li, Y., Li, J., Zhu, X., Xue, C., Chen, R., Zeng, Y., Wu, J., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101215 · Cited by 25

Causal Inference in Oncology: Why, What, How and When

van Amsterdam, W. A. C., Elias, S. G., & Ranganath, R. (2024) · Clinical Oncology · doi:10.1016/j.clon.2024.07.002 · Cited by 22

Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events

Khaled, N. B., Møller, M., Jochheim, L. S., Leyh, C., Ehmer, U., Böttcher, K., Pinter, M., Balcar, L., Scheiner, B., Weich, A., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101065 · Cited by 20

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer

Ladjevardi, C. O., Skribek, M., Koliadi, A., Ekström-Rydén, V., El‐Naggar, A. I., Digkas, E., Valachis, A., & Ullenhag, G. J. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03869-1 · Cited by 19

Comprehensive genome profiling for treatment decisions in patients with metastatic tumors: real-world evidence meta-analysis and registry data implementation

Zerdes, I., Filis, P., Fountoukidis, G., El‐Naggar, A. I., Kalofonou, F., D’Alessio, A., Pouptsis, A., Foukakis, T., Pentheroudakis, G. E., Ahlgren, J., et al. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf015 · Cited by 19

Efficacy, safety and differential outcomes of immune‐chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort

Mitzlaff, K., Kirstein, M. M., Müller, C., Venerito, M., Olkus, A., Dill, M. T., Weinmann, A., Kocheise, L., Busch, A., Schulze, K., et al. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12656 · Cited by 19

Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study

Jourdain, H., Meglio, A. D., Mansouri, I., Desplas, D., Zureik, M., & Haddy, N. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.104083 · Cited by 19

Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases

Grinda, T., Morganti, S., Hsu, L., Yoo, T.-K. R., Kusmick, R. J., Aizer, A. A., Giordano, A., Leone, J. P., Hughes, M. E., Tolaney, S. M., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00736-9 · Cited by 17

Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2− advanced/metastatic breast cancer: updated systematic review

Harbeck, N., Brufsky, A., Rose, C. G., Korytowsky, B., Chen, C., Tantakoun, K., Jazexhi, E., Nguyen, D. H. V., Bartlett, M., Samjoo, I. A., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1530391 · Cited by 20

Machine learning approaches for EGFR mutation status prediction in NSCLC: an updated systematic review

Haixian, L., Shu, P., Zhao, L., Chunfeng, L., & Lun, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1576461 · Cited by 19

A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression

Boman, C., Liu, X., Eriksson, L., Sun, W., Tranchell, C., Toli, M. A., Ács, B., Bergh, J. C. S., Foukakis, T., & Matikas, A. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02777-6 · Cited by 15

Artificial intelligence in myeloid malignancies: Clinical applications of machine learning in myelodysplastic syndromes and acute myeloid Leukemia

Al‐Nusair, J., Lanino, L., Durmaz, A., Porta, M. G. D., Zeidan, A. M., & Kewan, T. Z. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101340 · Cited by 13

Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancer

Bjerrum, A., Henriksen, A. F., Knoop, A. S., Berg, T., Tuxen, I. V., Lassen, U., & Petersen, T. S. (2024) · BJC Reports · doi:10.1038/s44276-024-00108-z · Cited by 13

A Review and Comparative Case Study Analysis of Real-World Evidence in European Regulatory and Health Technology Assessment Decision Making for Oncology Medicines

Zong, J., Rojubally, A., Pan, X., Wolf, B., Greenfeder, S. A., Upton, A. J., & Bergeson, J. G. (2024) · Value in Health · doi:10.1016/j.jval.2024.09.007 · Cited by 12

Exosomal biomarkers in leukemia: translational potential and regulatory challenges for precision medicine applications

Ansarian, M. A., Fatahichegeni, M., Wang, Y., Ren, J., Zhang, T., & Wang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1677088 · Cited by 14

Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan

Fabi, A., Rossi, A., Caputo, R., Pisegna, S., Scagnoli, S., Pantano, F., D’Auria, G., Fedele, P., Fabbri, A., Vernieri, C., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00801-3 · Cited by 12

Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study

Martínez‐Sáez, O., Tapia, M., Marín‐Aguilera, M., Hernández‐Illán, E., Tebar, C., Martínez-Puchol, A. I., Jares, P., Marín-Liébana, S., Magro, A., Puig‐Butillé, J. A., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2025.100123 · Cited by 12

Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC

Uehara, Y., Takeyasu, Y., Yoshida, T., Tateishi, A., Torasawa, M., Hosomi, Y., Masuda, K., Shinno, Y., Matsumoto, Y., Okuma, Y., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100058 · Cited by 12

Prognostic significance of tumour Ki-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort study

Toli, M. A., Liu, X., Massa, D., Lando, S., Boman, C., Tsiknakis, N., Tranchell, C., Papakonstantinou, A., Fotia, G., Vernieri, C., et al. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101432 · Cited by 11

Adaptive validation strategies for real-world clinical artificial intelligence

Kolbinger, F. R., & Kather, J. N. (2025) · Nature Computational Science · doi:10.1038/s43588-025-00901-x · Cited by 12

Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world study

M'Baloula, J., Tougeron, D., Boilève, A., Jeanbert, E., Guimbaud, R., Abdelghani, M. B., Durand, A., Turpin, A., Quesada, S., Blanc, J. F., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115051 · Cited by 11

Risk of colorectal cancer by family history of both colorectal carcinomas and colorectal polyps: a nationwide cohort study

Hu, Y., Kharazmi, E., Liang, Q., Brenner, H., Sundquist, J., Sundquist, K., & Fallah, M. (2025) · 癌症：英文版 · doi:10.1002/cac2.70059 · Cited by 10

Real-world evidence reported for clinical efficacy evaluation in European Public Assessment Reports of authorised targeted therapies for solid malignancies: a comprehensive review (2018-2022)

Derksen, J. W. G., Martins-Branco, D. A., Valachis, A., Pellat, A., van Nassau, S. C. M. W., Aggarwal, A. K., Pentheroudakis, G. E., Koopman, M., Castelo-Branco, L., & Delaloge, S. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100039 · Cited by 10

Oncology education in the age of artificial intelligence

Prelaj, A., Scoazec, G., Ferber, D., & Kather, J. N. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100079 · Cited by 10

First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study

Moliner, L., Zellweger, N. M., Schmid, S., Bertschinger, M., Waibel, C., Cerciello, F., Froesch, P., Mark, M. T., Bettini, A., Haeuptle, P., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100744 · Cited by 11

Characteristics of non-randomised studies of drug treatments: cross sectional study

Yaacoub, S. G., Porcher, R., Pellat, A., Bonnet, H., Tran, V.-T., Ravaud, P., & Boutron, I. (2024) · BMJ Medicine · doi:10.1136/bmjmed-2024-000932 · Cited by 10

Therapeutic Sequences of Systemic Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: Real‐World Analysis of the IMMUreal Cohort

Khaled, N. B., Zarka, V., Hobeika, B., Schneider, J. A., Rau, M., Weich, A., Leicht, H. B., Ye, L., Piseddu, I., Dill, M. T., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70090 · Cited by 10

Real-world evidence of the efficacy of neoadjuvant pembrolizumab in triple-negative breast cancer: A surgeon's point of view

Park, W. K., Nam, S. J., Kim, S. W., Yu, J. H., Lee, S. K., Ryu, J. M., Chae, B. J., Shin, D. S., Ahn, J. S., Park, Y. H., et al. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.110011 · Cited by 10

Real-world patterns of treatment and response in metastatic renal cell carcinoma: a multicentre UK-wide review with UK Renal Oncology Collaborative (UK ROC)

Frazer, R. D., McGrane, J., Challapalli, A., Ratnayake, G., Malik, J., Forde, C., Alam, S., Jones, E., Shaheen, A., Ferrara, A., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100027 · Cited by 12

Immune-related adverse events in patients treated with immunotherapy for locally advanced or metastatic NSCLC in real-world settings: a systematic review and meta-analysis

Pasello, G., Pavan, A., Nuzzo, M. D., Frega, S., Ferro, A., Maso, A. D., Bonanno, L., Guarneri, V., & Girardi, F. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1415470 · Cited by 9

The impact of inter-cycle treatment delays on 5-year all-cause mortality in early-stage breast cancer: A retrospective cohort study

Steventon, L., Kipps, E., Man, K. K. C., Roylance, R. R., Forster, M. D., Wong, I. C. K., Baser, M., Miller, R. E., Nicum, S., Shah, S., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114301 · Cited by 9

Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study

Fountzilas, E., Karageorgopoulou, S., Karakatsoulis, G., Tryfonopoulos, D. J., Papazisis, K., Koutras, A. K., Koumarianou, A. A., Zafeiri, G. C. M., Biziota, E., Nikolaidi, A., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100095 · Cited by 9

Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence

Loverro, M., Marchetti, C., Salutari, V., Giannarelli, D., Vertechy, L., Capomacchia, F. M., Caricato, C., Campitelli, M., Panico, C., Avesani, G., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2024.104119 · Cited by 9

Axillary surgery in early breast cancer: real-world analysis of the INSEMA-trial at three certified university breast cancer centers in Germany regarding the omission of sentinel lymph node biopsy

Tauber, N., Rambow, A.-C., Gasthaus, C., Fick, F., Grande-Nagel, I., Hilmer, L., Kohls, F., Krawczyk, N., Le, H. D., Elessawy, M., et al. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.110392 · Cited by 11

PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort

Cherifi, F., Cabel, L., Bousrih, C., Volant, E., Dalenc, F., Méry, B., Kuentz, M. A., Mailliez, A., Ladoire, S., de Nonneville, A. T., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105907 · Cited by 9

Patients with Advanced or Metastasised Non-Small-Cell Lung Cancer with Viscum album L. Therapy in Addition to PD-1/PD-L1 Blockade: A Real-World Data Study

Schad, F., Thronicke, A., Hofheinz, R., Matthes, H., & Grah, C. (2024) · Cancers · doi:10.3390/cancers16081609 · Cited by 9

Overall Survival and Economic Impact of Triple-Negative Breast Cancer in Brazilian Public Health Care: A Real-World Study

Mattar, A. P. L., Antonini, M., Amorim, A. G., Teixeira, M. D., de Resende, C. A. A., Cavalcante, F. P., Zerwes, F., Arakelian, R., Millen, E. C., Brenelli, F. P., et al. (2025) · JCO Global Oncology · doi:10.1200/go-24-00340 · Cited by 9

Stakeholders’ Perspectives Toward the Use of Patient Registry Data for Decision-Making on Medicines: A Cross-Sectional Survey

Windfuhr, F., de Vries, S. T., Melinder, M., Dahlqvist, T., Almeida, D., Sepodes, B. M. N., Torre, C., Wettermark, B., & Mol, P. G. M. (2025) · Drug Safety · doi:10.1007/s40264-025-01528-7 · Cited by 8

Prognosis After Pathologic Complete Response to Neoadjuvant Therapy in Early-Stage Breast Cancer: A Population-Based Study

Boman, C., Tranchell, C., Liu, X., Eriksson, L., Toli, M. A., Bergh, J. C. S., Foukakis, T., & Matikas, A. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.7093 · Cited by 8

Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settings

Takagi, K., Saito, G., Tanaka, H., Kubo, S., Shukuya, T., Tsugitomi, R., Sasaki, T., Oba, T., Mamesaya, N., Yamanaka, T., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105301 · Cited by 8

Impact of neoadjuvant compared to adjuvant chemotherapy on prognosis in patients with hormone-receptor positive / HER2-negative breast cancer: A propensity score matching population-based study

Hosseini-Mellner, S., Wickberg, Å., Karakatsanis, A., & Valachis, A. (2024) · The Breast · doi:10.1016/j.breast.2024.103741 · Cited by 8

Harnessing the Potential of Real-World Evidence in the Treatment of Colorectal Cancer: Where Do We Stand?

van Nassau, S. C. M. W., Bol, G. M., van der Baan, F. H., Roodhart, J. M. L., Vink, G. R., Punt, C. J. A., May, A. M., Koopman, M., & Derksen, J. W. G. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01186-4 · Cited by 8

Endometriosis and endometrial cancer: A propensity score-adjusted real-world data study

Farolfi, A., Gentili, N., Testoni, S., Rusconi, F., Massa, I., Danesi, V., Altavilla, A., Cursano, M. C., Gurioli, G., Burgio, S. L., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109680 · Cited by 8

Squamous cell carcinoma arising in chronically damaged skin (Marjolin’s Ulcer): still an unmet need in the era of immunotherapy

Miodovnik, M., Dolev, Y., Buchen, R., Brezis, M. R., Nikolaevski‐Berlin, A., Finkel, I., Wolf, I., Ospovat, I., Gutfeld, O., & Leshem, Y. (2024) · The Oncologist · doi:10.1093/oncolo/oyae326 · Cited by 7

Effectiveness of post-trastuzumab deruxtecan treatments and incidence of interstitial lung disease in HER2-positive metastatic breast cancer: a real-world, observational cohort study

Nozawa, K., Iwata, H., Mukohara, T., Taira, T., Yoshimura, A., Nagai, S. E., Hashimoto, J., Matsuura, K., Mizuno, T., Shinden, Y., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105511 · Cited by 7

Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer

Zattarin, E., Marra, A., Palazzo, A., Griguolo, G., Vernieri, C., Etessami, J. D., Pontolillo, L., Landa, G., Daneri, A., Monte, M. D., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00859-z · Cited by 8

Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry

Geurts, S. M. E., Ibragimova, K. I. E., Ding, N., Meegdes, M., Erdkamp, F., Heijns, J. B., Tol, J., Vriens, B. E. P. J., Dercksen, M. W., Aaldering, K. N. A., et al. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07235-0 · Cited by 9

Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: multicenter study using natural language processing on Belgian hospital data

Delombaerde, D. L., Oeste, C. L., Geldhof, V., Croes, L., Bassez, I., Verbiest, A., Tack, L., Hens, D. F. E., Franssen, C., Debruyne, P. R., et al. (2025) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100111 · Cited by 6

Occurrence of dMMR/MSI-H tumor during follow-up in Lynch syndrome patients treated with immune checkpoint inhibitors for metastatic digestive cancer between 2015 and 2024: a retrospective analysis of a monocentric prospective cohort study

Pellat, A., Loisel, C., Metras, J., Lefèvre, J. H., Parc, Y. R., Cohen, R., Samaille, T., Perrier, A., Dardenne, A., & André, T. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105559 · Cited by 6

Multimodal analysis of whole slide images in colorectal cancer

Jonnagaddala, J., Shulajkovska, M., Gradišek, A., Jue, T. R., Zhou, Q., Guo, Y., Chayeb, J. M. E., Li, R., Lipková, J., Kather, J. N., et al. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-02095-y · Cited by 10

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 15

Castañón, A., Bray, B., & Ramagopalan, S. V. (2024) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2024-0033 · Cited by 6

Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer

Ruckhäberle, E., Schmidt, M., Welt, A., Harbeck, N., Wöckel, A., Gluz, O., Park‐Simon, T., Untch, M., & Lux, M. P. (2024) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2344-5269 · Cited by 6

Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience

Ogliari, F. R., Traverso, A., Barbieri, S., Montagna, M., Chiabrando, F., Versino, E., Bosco, A., Lin, A., Ferrara, R., Oresti, S., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.108075 · Cited by 6

Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarcinoma in Spain

Álvarez-Gallego, R., Pazo-Cid, R., Vicente, B. L. D. S., Macarulla, T. M., Martinez, E., Garicano, F., Hernández, I., Granja, M., Ghanem, I., Martínez-Galán, J., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241309828 · Cited by 6

Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort

Epaillard, N., Lusque, A., Jacot, W., Mailliez, A., Bachelot, T., Arnedos, M., Du, F. L., Brain, E. G. C., Ferrero, J.-M., Massard, V., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103447 · Cited by 6

Integrating Aggressive-Variant Prostate Cancer-Associated Tumor Suppressor Gene Status with Clinical Variables to Refine Prognosis and Predict Androgen Receptor Pathway Inhibitor Response in Metastatic Hormone-Sensitive Setting

Pedrani, M., Salfi, G., Merler, S., Testi, I., Clerici, C. M. A., Pecoraro, G., Castelo-Branco, L., Turco, F., Tortola, L., Vogl, U. M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115309 · Cited by 5

Real-time data in cancer registries: Validation of an automated data extraction system

Langhout, S. A., Hermans, S. J. F., Smit, A. J. T., Berkx, E., Kurk, S. A., Schade, K. J., Posthuma, E. F. M., Visser, O. J., Cornelissen, J. J., Huijgens, P. C., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113056 · Cited by 5

Strategies for premedication and G-CSF application in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights

Pieniążek, M., Polakiewicz-Gilowska, A., Kubeczko, M., Las‐Jankowska, M., Pacholczak‐Madej, R., Miegem, P. K.-V., Ziobro, M., Łacko, A., Jarząb, M., & Püsküllüoğlu, M. (2025) · Supportive Care in Cancer · doi:10.1007/s00520-025-09918-4 · Cited by 5

Treatment gaps and survival outcomes of hepatocellular carcinoma: insights from a nationwide, claims-based study

Schrodi, S., Berger, K., Becht, S., von Bergwelt‐Baildon, M., Buggisch, P., Hofmann, W., Marschall, U., Lange, C. M., Reiter, F. P., Mayerle, J. V., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251363202 · Cited by 5

Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas

Sanogo, D., Levard, R., Cassecuel, J., Khammari, A., Quereux, G., Grange, F., Montaudié, H., Brunet‐Possenti, F., Lavaud, J., Leccia, M. ‐., et al. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.70136 · Cited by 5

Combination of Radiotherapy and Immunotherapy in Advanced Non–Small Cell Lung Cancer

Zhou, H., Wang, S.-C., Lee, T. T. L., Ye, Z., Fang, C.-B., Wai, A. K. C., Hu, C., & Kong, F. (2026) · JAMA Oncology · doi:10.1001/jamaoncol.2026.0392 · Cited by 6

Safety and efficacy of encorafenib–cetuximab combination in BRAF-mutated metastatic colorectal cancer: real-world evidence from the CONFIDENCE Spanish multicenter study

Montés, A. F., Ros, J., Alfonso, P. G., Graña, B., Brozos-Vázquez, E., Melián, M., Jiménez-Gordo, A.-M., de Castro, E. M., Busquier, I., Arias, A. F., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100055 · Cited by 4

Outcome and safety of lurbinectedin as compassionate use in extensive stage small cell lung cancer: A multicentric international cohort

Scattolin, D., Dingemans, A. C., Maso, A. D., Guarneri, V., Aerts, J. G. J. V., Pasello, G., & Dumoulin, D. W. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115595 · Cited by 4

Precision Oncology Guided by Genomic Profiling in Breast Cancer: Real-World Data from a Molecular Tumor Board

Graf, T., Boos, L. A., Mehra, T., Miglino, N., Sobottka, B., Rüschoff, J. H., Ibáñez, L. F., Zoche, M., Frauchiger-Heuer, H., Witzel, I., et al. (2025) · Cancers · doi:10.3390/cancers17152435 · Cited by 4

Impact of consolidation immunotherapy after definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: a real-world multicenter study

Yu, N., Chen, C., Wang, X., Ge, X., Yang, X., Li, J., Feng, G., Zheng, Z., Deng, L., Zhang, T., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115666 · Cited by 4

Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib

Ladoire, S., Kamga, A. M., Galland, L., Réda, M., Desmoulins, I., Mayeur, D., Kaderbhaï, C., Ilie, S. M., Hennequin, A., Talucier, H., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00726-x · Cited by 5

Real-World Evaluation of Immune-Related Endocrinopathies in Metastatic NSCLC Patients Treated with ICIs in Romania

Coniac, S., Costache-Outas, M. C., Antone-Iordache, I.-L., Barbu, A.-M., Bardan, V. T., Zamfir, A., Ionescu, A.-I., & Badiu, C. (2025) · Cancers · doi:10.3390/cancers17071198 · Cited by 4

Agnostic drug development revisited

Hernando‐Calvo, A., Rossi, A., Vieito, M., Voest, E. E., & Garralda, E. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102747 · Cited by 4

Beyond Clinical Trials: Understanding Neurotrophic Tropomyosin Receptor Kinase Inhibitor Challenges and Efficacy in Real-World Pediatric Oncology

Vince, C. S. C., Brassesco, M. S., Mançano, B. M., Gregianin, L. J., Carbone, E. K., Castro, A. D. A. E., Yamachira, V. S., da Silva, R. Z. M., Mariano, C. S., da Mata, J. F., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00713 · Cited by 3

Real-world prevalence, treatment and survival of “high risk” early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry

Ladoire, S., Kamga, A. M., Galland, L., Desmoulins, I., Mayeur, D., Kaderbhaï, C., Ilie, S. M., Hennequin, A., Jankowski, C., Albuisson, J., et al. (2024) · The Breast · doi:10.1016/j.breast.2024.103789 · Cited by 4

Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting

Stoff, R., Markovic, S. N., McWilliams, R. R., Kottschade, L. A., Montane, H. N., Dimou, A., Dudek, A. Z., Tan, W., Dronca, R. S., Seetharam, M., et al. (2024) · Melanoma Research · doi:10.1097/cmr.0000000000000997 · Cited by 5

Prognostic impact of depth of response and early tumour shrinkage in patients with BRAF V600E -mutated metastatic colorectal cancer treated with targeted therapy

Vetere, G., Germani, M. M., Antoniotti, C., Salvatore, L., Pietrantonio, F., Lonardi, S., Bensi, M., Ghelardi, F., Calegari, M. A., Intini, R., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241299975 · Cited by 4

Thyroid disorders as predictors of cemiplimab efficacy in recurrent/metastatic cervical cancer: real-world evidence from Poland

Pacholczak‐Madej, R., Lisik-Habib, M., Mądry, R., Szarszewska, M., Borysiewicz, Z., Gabalewicz, K., Iwańska, E., Szatkowski, W., Püsküllüoğlu, M., Jakubowicz, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1604826 · Cited by 4

Utilization and safety of trastuzumab emtansine (T-DM1): a nationwide population-based study using the French National Health Data System

Jourdain, H., Mansouri, I., Meglio, A. D., Zureik, M., & Haddy, N. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100045 · Cited by 4

How AI will transform cancer care

Kather, J. N., & Abernethy, A. P. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.08.2335 · Cited by 4

Real-World Evidence Acceptability and Use in Breast Cancer Treatment Decision-Making in the United States: Call-to-Action from a Multidisciplinary Think Tank

Khozin, S., Dreyer, N. A., Galante, D., Liu, R., Neumann, P., Nussbaum, N. C., O’Shaughnessy, J., Patt, D. A., Rimawi, M. F., Rugo, H. S., et al. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03201-y · Cited by 3

Complete responders in patients with HER2-positive metastatic breast cancer: a real-world SONABRE study

Ding, N., Visserman, R., Geurts, S. M. E., Tol, J., Vriens, B. E. P. J., Aaldering, K. N. A., Boon, E., Dercksen, M. W., van den Berkmortel, F. W. P. J., Pepels, M. J. A. E., et al. (2025) · The Breast · doi:10.1016/j.breast.2025.104583 · Cited by 3

Real-world survival outcomes of neoadjuvant versus adjuvant chemotherapy in operable triple-negative breast cancer: a propensity score matched registry-based study

El‐Naggar, A. I., Karakatsanis, A., & Valachis, A. (2025) · Acta Oncologica · doi:10.2340/1651-226x.2025.43990 · Cited by 3

Epidemiology and clinical characteristics of mesothelioma in the Chinese population: a multicenter study

Yang, S., Hao, Y., Wang, K., Xu, H., Huang, L., Xu, L., Meng, R., Li, B., Huang, J., Zhu, Y., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251378879 · Cited by 3

Sacituzumab Govitecan initial dose reduction in polish patients with metastatic triple-negative breast cancer: impact on efficacy and safety

Pieniążek, M., Kubeczko, M., Las‐Jankowska, M., Polakiewicz-Gilowska, A., Łacko, A., Jarząb, M., Bielčiková, Z., Pacholczak‐Madej, R., & Püsküllüoğlu, M. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04823-3 · Cited by 3

Time to Treatment Failure as an End Point in Pragmatic Oncology Trials: Association With Progression-Free Survival Across Randomized Studies

Dalrymple, J., Symons, R., Sjoquist, K. M., Lord, S., Woodford, R. G., Friedlander, M. L., Simes, R. J., & Lee, C. K. (2026) · JCO Precision Oncology · doi:10.1200/po-26-00011 · Cited by 3

Improving olaparib exposure to optimize adverse effects management

Sterlé, M., Puszkiel, A., Burlot, C., Pereira, E., Bellesœur, A., Percin, S. D., Beinse, G., Fumet, J.-D., Favier, L., Niogret, J., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241248328 · Cited by 4

Effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients with advanced/recurrent or metastatic esophageal squamous cell carcinoma in China: a real-world multicenter study

Yu, L., Shen, W., Ye, J., Luo, H., Zhang, X., Xu, Y., Lin, Q., Liu, W., Zhang, Y., Xu, Y., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241297092 · Cited by 3

Clinicopathological and molecular features of claudin-18 isoform 2 expression in patients with colorectal cancer: a single-center retrospective study

Takamizawa, S., Hirano, H., Takashima, A., Shoji, H., Hirose, T., Okita, N. T., Shiraishi, K., Sekine, S., Takamizawa, Y., Kanemitsu, Y., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241286774 · Cited by 3

Real-world analysis of HER2-ultralow in HR+/HER2– metastatic breast cancer: prevalence and first-line chemotherapy outcomes

Mathiot, L., Kerdraon, O., Borgne, F. L., Verrièle, V., Patsouris, A., Robert, M., Chetritt, J. J., Loussouarn, D., Campone, M., Bocquet, F., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251378863 · Cited by 3

Real-World Evidence in Oncology: Opportunities and Limitations

Maïo, M. D., Perrone, F., & Conte, P. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0647 · Cited by 181

Pré-test

Pellat, A., & Grinda, T. (2024) · Hépato-Gastro & Oncologie Digestive · doi:10.1684/hpg.2024.2812

Real-world evidence studies in oncology: a trend or a necessity?

Zhuravkov, A., Moiseenko, F. V., Колбин, А. С., & Moiseyenko, V. M. (2023) · Practical oncology · doi:10.31917/2401059 · Cited by 3

Longitudinal trends of real-world evidence (RWE) reporting in oncology conferences: An 11-year ASCO Annual Meeting analysis.

Azad, F., Zhang, J., Akhtar, O. S., George, A. M., Attwood, K. M., & Torka, P. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.e18748 · Cited by 1

Editorial: Real-world data and real-world evidence in lung cancer

Gristina, V., & Eze, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1436077 · Cited by 9